Oleg Nodelman
speaker
220 appearances
2 recordings
2 series
first heard Jun 2026
last heard 12 Jun
Oleg Nodelman’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Jun 2026 with 2.
Appearances
My fund, Eco R1 Capital, which is based in San Francisco, thinks of investing in biotech in a slightly different way.
We're looking for unfollowed, unloved, misunderstood biotech companies.
It's an amazing moment in time for those types of companies.
My name is Oleg Nodalman.
I'm the founder and managing director of EcoR1 Capital, a San Francisco-based value-oriented biotech fund that I started about 13 years ago.
Thanks a lot to the besties for having me here.
I'm a huge fan of the pod, like I'm sure all of us are, and I know how challenged Science Corner can get.
So I wrote this in a way that even David Sachs would appreciate and pay attention to if he were here.
Generally speaking, investing in biotech companies is a horrible idea sandwiched somewhere between movies, wineries and SPACs.
In fact, our sector often feels a lot more like a casino than an actual financial market.
And most of the tourists who are investing are playing the slots.
Of course, at EcoR1, we consider ourselves poker players.
In a sector where virtually everyone else is a momentum investor, betting on science, we focus on margin of safety.
We're one of the few funds not managed by PhDs or MDs, and that's by design, because we don't want to fall in love with the science.
We fall in love with the risk-reward.
And like the slide says, we want to monetize other kids' science projects.
This is my 25th year investing in biotech.
I started my career with an 11 year stint at another fund and launched Eco R1 in 2013, humble beginnings with 13 million.
Since inception, we've 10x to our investors and annualized at 20%.
And today we have about two and a half billion under management.
Showing 1–20 of 220 · page 1 of 11
Next →